10x Genomics earnings were -$157.0M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest TXG earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$34.4M, down 29.9% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, TXG reported annual earnings of -$182.6M, with -28.4% growth. The next TXG earnings date is Oct 28, 2025.
On TXG's earnings call on Invalid Date, 10x Genomics (NASDAQ: TXG) reported Q1 2025 earnings per share (EPS) of -$0.28, up 44% year over year. Total TXG earnings for the quarter were -$34.36 million. In the same quarter last year, 10x Genomics's earnings per share (EPS) was -$0.50.
The next TXG earnings date is Invalid Date. Add TXG to your watchlist to be reminded of 10x Genomics's next earnings date.
Is 10x Genomics profitable or losing money?
As of the last 10x Genomics earnings report, 10x Genomics is currently losing money. 10x Genomics's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$157.04 million, a 40.58% decrease year over year.
What was TXG's earnings growth in the past year?
As of 10x Genomics's earnings date in Invalid Date, 10x Genomics's earnings has grown year over year. TXG earnings in the past year totalled -$157.04 million.
What are 10x Genomics's earnings expectations?
The current EPS estimate for 10x Genomics's earnings report in Invalid Date is -$0.07.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.